MUMBAI and BALTIMORE, January 6, 2016 /PRNewswire/ --
Pharma Major Lupin Limited (Lupin) announced that its US subsidiary Lupin Pharmaceutical Inc. has launched its Tri-Lo-Marzia™ Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) having received approval from the United States Food and Drug Administration (FDA) to market a generic equivalent of Janssen Pharmaceuticals Inc. (Janssen) Ortho Tri-Cyclen® Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg).
(Logo: http://photos.prnewswire.com/prnh/20150903/762560-c )
Lupin’s Tri-Lo-Marzia™ Tablets (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg) are the AB rated generic equivalent of Janssen Ortho Tri-Cyclen® Lo Tablets, (Norgestimate and Ethinyl Estradiol Tablets USP, 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg). It is indicated for use by women to prevent pregnancy.
Ortho Tri-Cyclen® Lo Tablets had US sales of USD 488.4 million (IMS MAT September 2015). The product represents Lupin’s 16th oral contraceptive launch in the US. The company has filed 37 oral contraceptive products with the FDA till date.
About Lupin Limited:
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th - IMS Health). For the financial year ended 31st March 2015, Lupin’s Consolidated turnover and Profit after Tax were Rs. 125, 997 million (USD 2.06 billion) and Rs. 24, 032 million (USD 393 million) respectively.
Please visit http://www.lupin.com for more information. You could also follow us on Twitter -
http://www.twitter.com/lupinlimited
For further information or queries please contact -
Shamsher Gorawara
Head - Corporate Communications
Ph: +91-98 20 338 555
Email: shamshergorawara@lupin.com
*Safe Harbor Statement
Ortho Tri-Cyclen® Lo is the registered trademark of Johnson & Johnson Corporation.
SOURCE Lupin Ltd
